Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 12/20 | 0.52 |
| ▸ | NFE2L2 | Q16236 | 12/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4906067 | 0.93 | KEAP1 (0.53) | KEAP1NFE2L2SMN1; SMN2HTTALDH1A1 | |
| SCHEMBL4905129 | 0.87 | MMP13 (0.52) | KEAP1NFE2L2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4906333 | 0.80 | NPC1 (0.48) | KEAP1NFE2L2SMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL4905784 | 0.80 | LMNA (0.47) | KEAP1NFE2L2ATMSMN1; SMN2ALDH1A1 | |
| SCHEMBL4902970 | 0.79 | KEAP1 (0.48) | KEAP1NFE2L2ATMSMN1; SMN2KDM4E | |
| SCHEMBL4902733 | 0.79 | ESR1 (0.60) | ATMSMN1; SMN2KDM4EALDH1A1LMNA | |
| SCHEMBL4903818 | 0.79 | ESR1 (0.52) | ATMSMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4905993 | 0.78 | LMNA (0.56) | KEAP1NFE2L2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4904032 | 0.78 | KEAP1 (0.49) | KEAP1NFE2L2SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL4895775 | 0.78 | ALDH1A1 (0.48) | SMN1; SMN2HTTALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | HAMANAKA ERNEST S | 2006-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229363-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARA, PPARG, PPARD | KEAP1 714/4885NFE2L2 451/4885ATM 1568/4885 |
| US-20080090829-A1 | SUBSTITUTED HETEROARYL- AND PHENYLSULFAMOYL COMPOUNDS | PPARA, PPARG, PPARD | KEAP1 810/4885NFE2L2 446/4885ATM 1692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.